Frontpage Hero

Because we care, we need to act

Read more here

2017 Annual and Sustainability Report

"We have successfully launched our next-generation haemophilia products Elocta and Alprolix, and established a good position for them both in our main markets. Our track record of very strong quarter-on-quarter growth shows that we have managed to deliver consistently on our launch strategy. In the Annual Report, we have outlined how this growth will fuel our strategy to become global leaders in rare diseases, building on our capabilities and strengths within the field", says Guido Oelkers, CEO.

Click here to go to the on-line version of the annual report

Annual General Meeting 2018

The Annual General Meeting was held on Wednesday, May 9, 2018 at 15:00 at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.
More information about the AGM is found here.

Press releases

The Board of directors exercises authorisation for repurchase of shares to secure the company’s commitments under the incentive programme

The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi™) on 9 May 2018, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the Annual General Meeting – on a directed...

07/18/2018 - 08:10
Sobi™ publishes the report for the second quarter 2018

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the second quarter 2018. Total revenues grew 40 per cent compared with Q2 2017 (36 per cent at constant exchange rates, CER) and amounted to SEK 2,289 M. EBITA was SEK 951 M, an increase of 94...

07/18/2018 - 08:00
Invitation – Presentation of Sobi’s Q2 2018 results

On 18 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2018.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day...

07/02/2018 - 11:00
Sobi™ discloses payments to healthcare professionals and healthcare organisations to increase transparency

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the company has made all payments and transfers of value to healthcare professionals and organisations from 2017 publicly available*. This includes sponsorships to attend meetings, grants and donations,...

05/31/2018 - 14:00
Read more
Contact us

Sobi Head Office

info@sobi.com
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden
All contacts